This is a drug targeting heart disease hypertrophic cardiomyopathy (HCM) that was developed by Cytokinetics. Cytokinetics ...

Investing.com -- Shares of Cytokinetics (NASDAQ: CYTK ), Incorporated (NASDAQ:CYTK) climbed 4.8% after the company announced that Sanofi (NASDAQ: SNY) will acquire exclusive rights to develop and ...

As Cytokinetics’ aficamten awaits approval decisions from regulators in the U.S. and China, Sanofi has picked up China rights ...

Cytokinetics (CYTK) announced that Sanofi (SNY) will acquire exclusive rights to develop and commercialize aficamten from Corxel ...

Cytokinetics, Inc.(CYTK), a late-stage, specialty cardiovascular biopharmaceutical company, Friday announced that French drug major ...

SOUTH SAN FRANCISCO, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CYTK) today announced that Sanofi will acquire ...

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Sanofi will acquire exclusive rights to develop and commercialize aficamten ...

It has been about a month since the last earnings report for Cytokinetics (CYTK). Shares have lost about 9.7% in that time frame, underperforming the S&P 500. Will the recent negative trend ...

Sanofi has announced plans to invest approximately €1bn to build a new insulin production base in China. The site, located in the Beijing Economic and Technological Development Zone, will be aimed at ...

Cytokinetics has a 12-month low of $32.50 and a 12-month high of $110.25. Cytokinetics ( NASDAQ:CYTK – Get Free Report ) last released its quarterly earnings results on Wednesday, November 6th.